Our study includes numerous such examples, supported by the recent launch of new drugs such as evinacumab, a monoclonal antibody targeting angiopoietin-like 3 (ANGPTL3) to treat dyslipidemia, or the SLC10A2 inhibitor odevixibat to treat cholestasis. Here, ANGPTL3 is linked to cholestasis.